Novel Molecular Targets for the Therapy of Urothelial Cancer.
Anticancer Res
; 35(9): 4557-67, 2015 Sep.
Article
em En
| MEDLINE
| ID: mdl-26254343
ABSTRACT
First-line platinum-based chemotherapy combinations are considered standard-of-care in locally advanced and metastatic urothelial cancer. However, long-term outcomes, including disease-specific and overall survival, remain poor. In addition, a number of patients with advanced urothelial carcinoma have co-existing medical issues that preclude the use of conventional chemotherapy. Improvements in our understanding over the molecular mechanisms of urothelial cancer have led to first-generation clinical trials evaluating novel agents targeting molecular pathways that may be relevant, at least in sub-populations. Emerging information regarding outcome with agents targeting novel molecular targets in advanced urothelial cancer is discussed in this review.
Palavras-chave
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células de Transição
/
Urotélio
/
Terapia de Alvo Molecular
Limite:
Humans
Idioma:
En
Revista:
Anticancer Res
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Estados Unidos